2024
Glis2 is an early effector of polycystin signaling and a target for therapy in polycystic kidney disease
Zhang C, Rehman M, Tian X, Pei S, Gu J, Bell T, Dong K, Tham M, Cai Y, Wei Z, Behrens F, Jetten A, Zhao H, Lek M, Somlo S. Glis2 is an early effector of polycystin signaling and a target for therapy in polycystic kidney disease. Nature Communications 2024, 15: 3698. PMID: 38693102, PMCID: PMC11063051, DOI: 10.1038/s41467-024-48025-6.Peer-Reviewed Original ResearchConceptsMouse models of autosomal dominant polycystic kidney diseaseModel of autosomal dominant polycystic kidney diseasePolycystin signalingAutosomal dominant polycystic kidney diseasePolycystin-1Polycystic kidney diseaseTreat autosomal dominant polycystic kidney diseaseGlis2Primary ciliaKidney tubule cellsSignaling pathwayMouse modelDominant polycystic kidney diseasePotential therapeutic targetTranslatomeAntisense oligonucleotidesKidney diseasePolycystinMouse kidneyFunctional effectorsCyst formationTherapeutic targetInactivationFunctional targetPharmacological targets
2015
Effect of predicted protein-truncating genetic variants on the human transcriptome
Rivas MA, Pirinen M, Conrad DF, Lek M, Tsang EK, Karczewski KJ, Maller JB, Kukurba KR, DeLuca DS, Fromer M, Ferreira PG, Smith KS, Zhang R, Zhao F, Banks E, Poplin R, Ruderfer DM, Purcell SM, Tukiainen T, Minikel EV, Stenson PD, Cooper DN, Huang KH, Sullivan TJ, Nedzel J, Consortium T, Consortium T, Bustamante CD, Li JB, Daly MJ, Guigo R, Donnelly P, Ardlie K, Sammeth M, Dermitzakis ET, McCarthy MI, Montgomery SB, Lappalainen T, MacArthur DG, Segre A, Young T, Gelfand E, Trowbridge C, Ward L, Kheradpour P, Iriarte B, Meng Y, Palmer C, Esko T, Winckler W, Hirschhorn J, Kellis M, Getz G, Shablin A, Li, Zhou Y, Nobel A, Rusyn I, Wright F, Battle A, Mostafavi S, Mele M, Reverter F, Goldmann J, Koller D, Gamazon E, Im H, Konkashbaev A, Nicolae D, Cox N, Flutre T, Wen X, Stephens M, Pritchard J, Tu Z, Zhang B, Huang T, Long Q, Lin L, Yang J, Zhu J, Liu J, Brown A, Mestichelli B, Tidwell D, Lo E, Salvatore M, Shad S, Thomas J, Lonsdale J, Choi R, Karasik E, Ramsey K, Moser M, Foster B, Gillard B, Syron J, Fleming J, Magazine H, Hasz R, Walters G, Bridge J, Miklos M, Sullivan S, Barker L, Traino H, Mosavel M, Siminoff L, Valley D, Rohrer D, Jewel S, Branton P, Sobin L, Barcus M, Qi L, Hariharan P, Wu S, Tabor D, Shive C, Smith A, Buia S, Undale A, Robinson K, Roche N, Valentino K, Britton A, Burges R, Bradbury D, Hambright K, Seleski J, Korzeniewski G, Erickson K, Marcus Y, Tejada J, Taherian M, Lu C, Robles B, Basile M, Mash D, Volpi S, Struewing J, Temple G, Boyer J, Colantuoni D, Little R, Koester S, Carithers L, Moore H, Guan P, Compton C, Sawyer S, Demchok J, Vaught J, Rabiner C, Lockhart N, Friedlander M, Hoen P, Monlong J, GonzĂ lez-Porta M, Kurbatova N, Griebel T, Barann M, Wieland T, Greger L, van Iterson M, Almlof J, Ribeca P, Pulyakhina I, Esser D, Giger T, Tikhonov A, Sultan M, Bertier G, Lizano E, Buermans H, Padioleau I, Schwarzmayr T, Karlberg O, Ongen H, Kilpinen H, Beltran S, Gut M, Kahlem K, Amstislavskiy V, Stegle O, Flicek P, Strom T, Lehrach H, Schreiber S, Sudbrak R, Carracedo A, Antonarakis S, Hasler R, Syvanen A, van Ommen G, Brazma A, Meitinger T, Rosenstiel P, Gut I, Estivill X. Effect of predicted protein-truncating genetic variants on the human transcriptome. Science 2015, 348: 666-669. PMID: 25954003, PMCID: PMC4537935, DOI: 10.1126/science.1261877.Peer-Reviewed Original ResearchConceptsGenotype-Tissue ExpressionGenetic variantsProtein-truncating variantsEffects of variantsDosage compensationClass of variantsTranscript decayGene functionTranscriptome dataHuman transcriptomeGenetic variationGEUVADIS projectGene inactivationSplice junctionsGenome interpretationTranscriptome effectsFunctional interpretationClinical genome interpretationFunctional effectsPositional effectsImproved predictive modelVariantsTranscriptomeProfound effectInactivation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply